Skip to main content
Industry News
HCV combo's shorter treatment duration effective in genotype 3

Researchers found through an analysis of pooled data from various midstage and late-stage trials that an abbreviated, eight-week treatment duration of glecaprevir/pibrentasvir to treat noncirrhotic hepatitis C virus patients with genotype 3 was effective. The findings were reported online in the Journal of Viral Hepatitis.

Full Story: